Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 25,931 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 25,931 shares of Natera stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $4,277,837.07. Following the completion of the sale, the chief financial officer now owns 109,665 shares of the company’s stock, valued at $18,091,435.05. The trade was a 19.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, October 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $126.45, for a total transaction of $235,955.70.
• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $118.21, for a total transaction of $146,343.98.
• On Friday, October 25th, Michael Burkes Brophy sold 691 shares of Natera stock. The shares were sold at an average price of $118.81, for a total value of $82,097.71.

Natera Stock Performance

NTRA opened at $171.93 on Thursday. The firm has a 50 day moving average of $165.35 and a two-hundred day moving average of $135.41. The firm has a market capitalization of $22.70 billion, a PE ratio of -97.69 and a beta of 1.65. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12-month low of $62.96 and a 12-month high of $183.00.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same quarter last year, the company posted ($0.95) earnings per share. The firm’s revenue was up 63.9% compared to the same quarter last year. On average, analysts anticipate that Natera, Inc. will post -1.61 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. raised their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. TD Cowen raised their price target on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. The Goldman Sachs Group boosted their price objective on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Canaccord Genuity Group raised their target price on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Finally, Piper Sandler upped their price target on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $160.63.

Institutional Trading of Natera

Hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in Natera by 35.6% during the second quarter. Dimensional Fund Advisors LP now owns 264,801 shares of the medical research company’s stock valued at $28,680,000 after acquiring an additional 69,523 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Natera during the 2nd quarter worth approximately $767,000. Amalgamated Bank increased its holdings in shares of Natera by 6.0% during the 2nd quarter. Amalgamated Bank now owns 7,590 shares of the medical research company’s stock valued at $822,000 after purchasing an additional 428 shares in the last quarter. XTX Topco Ltd lifted its stake in shares of Natera by 24.1% in the 2nd quarter. XTX Topco Ltd now owns 4,846 shares of the medical research company’s stock valued at $525,000 after purchasing an additional 940 shares during the period. Finally, Benjamin F. Edwards & Company Inc. boosted its holdings in Natera by 4,082.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,821 shares of the medical research company’s stock worth $847,000 after buying an additional 7,634 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.